BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/4/2017 8:16:34 AM | Browse: 930 | Download: 1404
 |
Received |
|
2016-09-05 11:07 |
|
Peer-Review Started |
|
2016-09-05 14:12 |
|
To Make the First Decision |
|
2016-10-20 08:31 |
|
Return for Revision |
|
2016-11-02 16:46 |
|
Revised |
|
2016-12-05 02:02 |
|
Second Decision |
|
2017-01-13 17:45 |
|
Accepted by Journal Editor-in-Chief |
|
2017-01-14 00:37 |
|
Accepted by Executive Editor-in-Chief |
|
2017-01-18 10:28 |
|
Articles in Press |
|
2017-01-18 10:28 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-04-28 10:06 |
|
Publish the Manuscript Online |
|
2017-05-04 08:16 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Anna Viola, Giuseppe Costantino, Antonino Carlo Privitera, Fabrizio Bossa, Angelo Lauria, Laurino Grossi, Maria Beatrice Principi, Nicola Della Valle and Maria Cappello |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Maria Cappello, MD, Gastroenterology and Hepatology Section, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Piazza Delle Cliniche 2, 90127 Palermo, Italy. marica.cappello61@gmail.com |
| Key Words |
Infliximab; One-hour infusion; Cost savings; Economic impact; Multicenter study |
| Core Tip |
Infliximab (IFX) is a monoclonal antibody anti-tumour necrosis factor used in the treatment of moderate-to-severe inflammatory bowel diseases refractory to conventional therapy. It is usually administered i.v. at a dose of 5 mg/kg as a 2-h infusion. Shortening the infusion protocol to 1 h is equally safe and positively affects quality of life. This paper analyzes the impact of short IFX infusion on hospital resource utilization and costs, both in terms of time saving and increased infusion unit capacity. In addition, we provide evidence of indirect patient-related cost savings. |
| Publish Date |
2017-05-04 08:16 |
| Citation |
Viola A, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Cappello M. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study. World J Gastrointest Pharmacol Ther 2017; 8(2): 131-136 |
| URL |
http://www.wjgnet.com/2150-5349/full/v8/i2/131.htm |
| DOI |
http://dx.doi.org/10.4292/wjgpt.v8.i2.131 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
